Cargando…

A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide

The standard‐of‐care for patients with acute promyelocytic leukemia (APL) relapsing after upfront arsenic trioxide (ATO) therapy is not defined. The present study was undertaken to evaluate the safety of addition of bortezomib to ATO in the treatment of relapsed APL based on our previously reported...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kulkarni, Uday, Ganesan, Saravanan, Alex, Ansu Abu, Palani, Hamenth, David, Sachin, Balasundaram, Nithya, Venkatraman, Arvind, Thenmozhi, Mani, Jeyaseelan, Lakshmanan, Korula, Anu, Devasia, Anup, Abraham, Aby, Janet, Nancy Beryl, Balasubramanian, Poonkuzhali, George, Biju, Mathews, Vikram
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7163093/ https://www.ncbi.nlm.nih.gov/pubmed/32059085 http://dx.doi.org/10.1002/cam4.2883

Ejemplares similares

Management of relapse in acute promyelocytic leukaemia treated with up‐front arsenic trioxide‐based regimens
por: Fouzia, N. A., et al.
Publicado: (2020)

Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia
por: Kulkarni, Uday P., et al.
Publicado: (2022)

Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia
por: Balasundaram, Nithya, et al.
Publicado: (2022)

Arsenic Trioxide Enhances the NK Cell Cytotoxicity Against Acute Promyelocytic Leukemia While Simultaneously Inhibiting Its Bio-Genesis
por: Alex, Ansu Abu, et al.
Publicado: (2018)

Stromal cells downregulate miR-23a-5p to activate protective autophagy in acute myeloid leukemia
por: Ganesan, Saravanan, et al.
Publicado: (2019)

Haploidentical Natural Killer Cell Therapy as an Adjunct to Stem Cell Transplantation for Treatment of Refractory Acute Myeloid Leukemia
por: Kulkarni, Uday, et al.
Publicado: (2023)

Intracranial bleeding in acute promyelocytic leukemia treated with arsenic trioxide based regimens is associated with induction mortality but not with relapse
por: Kulkarni, Uday Prakash, et al.
Publicado: (2023)

Comparison of Newly Diagnosed and Relapsed Patients with Acute Promyelocytic Leukemia Treated with Arsenic Trioxide: Insight into Mechanisms of Resistance
por: Chendamarai, Ezhilarasi, et al.
Publicado: (2015)

Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia
por: Ganesan, S, et al.
Publicado: (2016)

Adult Acute Lymphoblastic Leukemia: Limitations of Intensification of Therapy in a Developing Country
por: Jain, Punit, et al.
Publicado: (2018)

Treatment of Acute Promyelocytic Leukemia with Single-Agent Arsenic Trioxide
por: Mathews, Vikram, et al.
Publicado: (2011)

Mutation profile in BCR-ABL1-negative myeloproliferative neoplasms: A single-center experience from India
por: Maddali, Madhavi, et al.
Publicado: (2021)

Prognostic plasma biomarkers of early complications and graft‐versus‐host disease in patients undergoing allogeneic hematopoietic stem cell transplantation
por: Balakrishnan, Balaji, et al.
Publicado: (2020)

NUDT15 c.415C>T Polymorphism Predicts 6-MP Induced Early Myelotoxicity in Patients with Acute Lymphoblastic Leukemia Undergoing Maintenance Therapy
por: Pai, Aswin Anand, et al.
Publicado: (2021)

Hematopoietic Stem Cell Transplantation is a cost-effective alternative to enzyme replacement therapy in Gaucher Disease
por: Aboobacker, Fouzia N, et al.
Publicado: (2022)

Speckle tracking echocardiography-derived left ventricular global longitudinal strain in ex-thalassaemics
por: Paul, Amal, et al.
Publicado: (2023)

Allogeneic Stem Cell Transplant for Acute Myeloid Leukemia: Evolution of an Effective Strategy in India
por: Ganapule, Abhijeet, et al.
Publicado: (2017)

A Review of Arsenic Trioxide and Acute Promyelocytic Leukemia
por: Alimoghaddam, Kamran
Publicado: (2014)

On arsenic trioxide in the clinical treatment of acute promyelocytic leukemia
por: Zhang, Peng
Publicado: (2017)

Plasma imatinib levels and ABCB1 polymorphism influences early molecular response and failure-free survival in newly diagnosed chronic phase CML patients
por: Rajamani, Bharathi M., et al.
Publicado: (2020)

Acute myeloid leukaemia: challenges and real world data from India
por: Philip, Chepsy, et al.
Publicado: (2015)

Arsenic trioxide rewires mantle cell lymphoma response to bortezomib
por: Zhao, Ling-Ling, et al.
Publicado: (2015)

Arsenic trioxide for acute promyelocytic leukemia in a patient on chronic hemodialysis
por: Tinajero, Jose, et al.
Publicado: (2022)

Fludarabine-Based Low-Intensity Conditioning for Fanconi Anemia is Associated with Good Outcomes in Aplastic Anemia but not in MDS - a Single-Center Experience
por: Chattopadhyay, Sohini, et al.
Publicado: (2023)

Arsenic trioxide induces depolymerization of microtubules in an acute promyelocytic leukemia cell line
por: Baek, Jin Ho, et al.
Publicado: (2012)

Feasibility of oral arsenic trioxide treatment for acute promyelocytic leukemia during hemodialysis
por: Au, Wing-Yan, et al.
Publicado: (2012)

Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives
por: McCulloch, Derek, et al.
Publicado: (2017)

Ascorbic Acid Potentiation of Arsenic Trioxide Anticancer Activity Against Acute Promyelocytic Leukemia
por: Yedjou, Clement, et al.
Publicado: (2009)

Arsenic speciation in saliva of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment
por: Chen, Baowei, et al.
Publicado: (2013)

Retinoic acid and arsenic trioxide sensitize acute promyelocytic leukemia cells to ER stress
por: Masciarelli, S, et al.
Publicado: (2018)

All-trans-retinoic-acid and arsenic trioxide induced remission in promyelocytic blast crisis
por: Colvin, Teresa A., et al.
Publicado: (2018)

Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives [Corrigendum]
Publicado: (2017)

Blood Parameters in Treatment with Arsenic Trioxide in Acute Promyelocytic Leukemia: A Systematic Review
por: Mohammadi Kanesbi, Mehdi, et al.
Publicado: (2020)

Successful treatment of acute promyelocytic leukemia in a patient under hemodialysis with arsenic trioxide
por: Hashimoto, Akiko, et al.
Publicado: (2021)

Successful treatment of acute promyelocytic leukemia in a patient undergoing hemodialysis with arsenic trioxide
por: Hashimoto, Akiko, et al.
Publicado: (2021)

Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia
por: Epstein-Peterson, Zachary D., et al.
Publicado: (2022)

The Development and Clinical Applications of Oral Arsenic Trioxide for Acute Promyelocytic Leukaemia and Other Diseases
por: Chin, Lynn, et al.
Publicado: (2022)

Single Dose of Ivermectin is not Useful in Patients with Hematological Disorders and COVID-19 Illness: A Phase II B Open Labelled Randomized Controlled Trial
por: George, Biju, et al.
Publicado: (2022)

Unusual massive bone marrow fibrosis in acute promyelocytic leukemia following arsenic trioxide therapy
por: Venkatesan, S., et al.
Publicado: (2015)

Role of Signal Regulatory Protein α in Arsenic Trioxide-induced Promyelocytic Leukemia Cell Apoptosis
por: Pan, Chaoyun, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vehsq2cnts8kf78aacl75n55lh